Samlyn Capital’s Cabaletta Bio CABA Stock Holding History

Samlyn Capital’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,919,907	Closed	-$2.04M	–	93
2022 Q2	$2.04M	Buy	1,919,907 +151,824	+9%	+$215K	0.04%	79
2022 Q1	$3.59M	Buy	1,768,083 +384,702	+28%	+$1.01M	0.05%	94
2021 Q4	$5.24M	Buy	1,383,381 +1,033,906	+296%	+$11M	0.07%	103
2021 Q3	$4.25M	Buy	+349,475	New	+$3.22M	0.06%	111

Other funds holding CABA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Samlyn Capital's CABA Position: Q3 2022 in Review

Samlyn Capital sold out of Cabaletta Bio (CABA) in Q3 2022, closing a stake of 1,919,907 shares — an estimated $2.04M sold.

Samlyn Capital first reported a position in CABA in Q3 2021 and held it in 4 quarters. The position peaked at $5.24M in Q4 2021. 54 funds tracked by Wall St. Rank hold CABA as of Q3 2022.

Samlyn Capital reported no remaining Cabaletta Bio position as of Q3 2022 after selling out during the quarter.
Samlyn Capital sold 1,919,907 Cabaletta Bio shares in Q3 2022, an estimated $2.04M.
Samlyn Capital first reported a position in Cabaletta Bio in Q3 2021 and held it in 4 quarters.
Samlyn Capital's Cabaletta Bio position peaked at $5.24M in Q4 2021.
54 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2022.

Based on Samlyn Capital's 13F filing for Q3 2022, filed 14 Nov 2022.